Uncategorized
EXCLUSIVE: AdvisorShares Portfolio Manager Says Market ‘Nervous’ In 2025, Encourages Investors To Have ‘Long-Term Focus’
An ETF portfolio manager highlights how his fund is beating the broader market and what advice he has for investors in 2025 in an exclusive Benzinga interview. read more
Atmus Filtration’s Path To Growth: Analyst Highlights Strong Financials, Tariff Pricing Power
JP Morgan maintains an Overweight rating on Atmus Filtration, raising the price target to $46 due to strong growth potential and tariff pricing power. read more
Soleno Shares Are Up Today: What’s Going On?
Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares are trading higher Thursday after the company announced it secured FDA approval for its first commercial drug, Vykat XR (diazoxide choline) extended-release tablets. read more
Ultragenyx Stays On JPMorgan’s Focus List As Analyst Highlights Strong Long-Term Positioning
JP Morgan sees strong upside for Ultragenyx, citing setrusumab trial progress and pipeline growth, raising the price target to $117. Latest Ratings for RARE Date Firm Action From To Feb 2022 Morgan Stanley Maintains Overweight Feb 2022 JP Morgan Upgrades Neutral Overweight Feb 2022 Morgan Stanley Maintains Overweight View More Analyst Ratings for RARE View…
Candel Therapeutics Shares Are Down Today: What’s Going On?
Candel Therapeutics, Inc. (NASDAQ: CADL) shares are are trading lower Thursday after the company released final survival data from its phase 2a clinical trial of CAN-2409. read more
Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug
BridgeBio’s acoramidis wins Japan’s approval for ATTR-CM. Phase 3 data show a 42% reduction in key heart-related events. AstraZeneca’s Alexion to market it. read more
Chemomab Therapeutics’ Touts Positive Data From Experimental Drug For Chronic Liver Disease
Chemomab’s OLE study of nebokitug in PSC patients confirmed safety and showed improvements in liver stiffness, fibrosis biomarkers, and cholestasis markers. read more
Vertical Aerospace Unfairly Undervalued, Says Bullish Analyst
Analyst initiates coverage on Vertical Aerospace Ltd. with Buy rating and $15 price forecast. Company’s progress and partnerships position it well in eVTOL market. Latest Ratings for EVTL Date Firm Action From To Jan 2022 Barclays Initiates Coverage On Underweight View More Analyst Ratings for EVTL View the Latest Analyst Ratings read more
BlackRock Unveils New iShares iBonds ETFs For Fixed-Income Investors
BlackRock has launched two new target maturity ETFs, IBCA and IBIL, which blend features of bonds with stock-like trading for consistent returns. read more
Goldman Sachs Sees More Upside In Real Estate Data As February Volumes Surge And Revisions Trend Higher
Goldman Sachs analyst reports strong growth in US real estate market in February, with increases in transaction volumes for office and retail sectors. Additional revisions are expected in March. Latest Ratings for NMRK Date Firm Action From To Mar 2022 Wolfe Research Downgrades Outperform Peer Perform Nov 2021 Raymond James Maintains Outperform Aug 2021 Raymond…